Header Logo

JAN ANDREAS BURGER

TitleAssociate Professor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kim E, Chen SS, Sivina M, Hwang H, Huang X, Ferrajoli A, Jain N, Wierda WG, Wodarz D, Chiorazzi N, Burger JA. Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood. 2024 Oct 23. PMID: 39441901.
      Citations:    Fields:    
    2. DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533. PMID: 39300320.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Roessner PM, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, Boskovic P, Beckendorff J, Roider T, Arseni L, Coelho M, Chakraborty S, Vaca A, Sivina M, Muckenhuber M, Rodriguez-Rodriguez S, Bonato A, Herbst SA, Zapatka M, Sun C, Kretzmer H, Naake T, Bruch PM, Czernilofsky F, Ten Hacken E, Schneider M, Helm D, Yosifov DY, Kauer J, Danilov AV, Bewarder M, Heyne K, Schneider C, Stilgenbauer S, Wiestner A, Mallm JP, Burger JA, Efremov DG, Lichter P, Dietrich S, Mart?n-Subero JI, Rippe K, Seiffert M, Roessner PM, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, Boskovic P, Benckendorff J, Roider T, Arseni L, Coelho M, Chakraborty S, Vaca AM, Sivina M, Muckenhuber M, Rodriguez-Rodriguez S, Bonato A, Herbst SA, Zapatka M, Sun C, Kretzmer H, Naake T, Bruch PM, Czernilofsky F, Ten Hacken E, Schneider M, Helm D, Yosifov DY, Kauer J, Danilov AV, Bewarder M, Heyne K, Schneider C, Stilgenbauer S, Wiestner A, Mallm JP, Burger JA, Efremov DG, Lichter P, Dietrich S, Martin-Subero JI, Rippe K, Seiffert M. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. Blood. 2024 Aug 01; 144(5):510-524. PMID: 38684038; PMCID: PMC11307267.
      Citations:    Fields:    Translation:HumansAnimalsCells
    4. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA, Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8(10):2342-2350. PMID: 38537065; PMCID: PMC11127193.
      Citations:    Fields:    Translation:Humans
    5. Ghia P, Owen C, Allan JN, Barrientos JC, Barr PM, Shi C, Szoke A, Abbazio C, Krigsfeld GS, Burger JA. First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis. Hemasphere. 2024 May; 8(5):e74. PMID: 38803455; PMCID: PMC11129546.
      Citations:    
    6. Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma. 2024 Sep; 65(9):1325-1334. PMID: 38749022.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Safa FM, Rasmussen T, Fontan L, Xia M, Melnick A, Wiestner A, Lobelle-Rich P, Burger JA, Mouawad Y, Safah H, Flemington EK, Saba NS. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application. Haematologica. 2024 05 01; 109(5):1348-1358. PMID: 37767562; PMCID: PMC11063839.
      Citations:    Fields:    
    8. Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360. PMID: 37585491.
      Citations:    Fields:    Translation:Humans
    9. Koehrer S, Burger JA. Chronic Lymphocytic Leukemia: Disease Biology. Acta Haematol. 2024; 147(1):8-21. PMID: 37717577.
      Citations: 2     Fields:    Translation:HumansCells
    10. Turcotte AE, Glass WF, Lin JS, Burger JA. Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report. Leuk Res Rep. 2023; 20:100377. PMID: 37457553; PMCID: PMC10338352.
      Citations:    
    11. Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma. 2023 09; 64(9):1554-1561. PMID: 37317991.
      Citations:    Fields:    Translation:Humans
    12. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966. PMID: 36287248; PMCID: PMC10189379.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    13. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 2023 07 15; 129(14):2192-2200. PMID: 37016930; PMCID: PMC10882584.
      Citations:    Fields:    Translation:Humans
    14. Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Komblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq. 2023 Feb 23. PMID: 36865338; PMCID: PMC9980221.
      Citations:    
    15. Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA. Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for =5 Years in the RESONATE-2 Study. Cancers (Basel). 2023 Jan 13; 15(2). PMID: 36672456; PMCID: PMC9857192.
      Citations: 1     
    16. Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Jermain M, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8?Years: A Plain Language Summary. Future Oncol. 2023 01 09. PMID: 36617990.
      Citations:    Fields:    
    17. Reiss EIMM, van Haaren MM, van Schooten J, Claireaux MAF, Maisonnasse P, Antanasijevic A, Allen JD, Bontjer I, Torres JL, Lee WH, Ozorowski G, V?zquez Bernat N, Kaduk M, Aldon Y, Burger JA, Chawla H, Aartse A, Tolazzi M, Gao H, Mundsperger P, Crispin M, Montefiori DC, Karlsson Hedestam GB, Scarlatti G, Ward AB, Le Grand R, Shattock R, Dereuddre-Bosquet N, Sanders RW, van Gils MJ. Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. NPJ Vaccines. 2022 Nov 25; 7(1):152. PMID: 36433972; PMCID: PMC9700725.
      Citations:    
    18. Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Mu?oz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, L?pez-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Mart?n-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 11; 54(11):1664-1674. PMID: 35927489; PMCID: PMC10084830.
      Citations:    
    19. Owen C, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Barr PM, Robak T, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 06 14; 6(11):3440-3450. PMID: 35377947; PMCID: PMC9198904.
      Citations:    Fields:    Translation:Humans
    20. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012. PMID: 35567779; PMCID: PMC9354943.
      Citations:    Fields:    Translation:Humans
    21. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855. PMID: 35595309; PMCID: PMC9308680.
      Citations:    Fields:    Translation:HumansCells
    22. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170. PMID: 35442137.
      Citations:    Fields:    
    23. Mukherjee A, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF, Milton DR. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893. PMID: 35225133; PMCID: PMC9730341.
      Citations:    Fields:    Translation:Humans
    24. Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia. 2022 05; 36(5):1324-1335. PMID: 35149845.
      Citations: 1     Fields:    Translation:HumansCells
    25. Mazzarello AN, Tarasenko TN, Ferrer G, Vergani S, Liu Y, Bagnara D, Rai KR, Burger JA, McGuire PJ, Maity PC, Jumaa H, Chiorazzi N, Gentner-G?bel E, D?hren-von Minden M, Nicol? A. B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. J Clin Invest. 2022 01 18; 132(2). PMID: 34813501; PMCID: PMC8759784.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    26. Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386. PMID: 35014928.
      Citations: 1     Fields:    Translation:Humans
    27. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-na?ve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 03; 196(5):1209-1218. PMID: 34915592; PMCID: PMC9300083.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    28. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592. PMID: 34521099; PMCID: PMC8832441.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    29. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722. PMID: 34625713.
      Citations: 1     Fields:    Translation:Humans
    30. Burger JA. CLL cells are moved by the MARCKS brothers. Blood. 2021 08 19; 138(7):503-504. PMID: 34410355; PMCID: PMC9999035.
      Citations:    Fields:    Translation:Humans
    31. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383; PMCID: PMC8193546.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    32. Burger JA. Integrating New Therapies for Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01; 27(4):275-285. PMID: 34398554.
      Citations: 1     Fields:    Translation:Humans
    33. Smith CIE, Burger JA. Resistance Mutations to BTK Inhibitors Originate From the NF-?B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol. 2021; 12:689472. PMID: 34177947; PMCID: PMC8222783.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    34. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924. PMID: 33901324.
      Citations: 4     Fields:    Translation:Humans
    35. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    36. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 07; 194(1):61-68. PMID: 33973230; PMCID: PMC9284944.
      Citations: 1     Fields:    Translation:Humans
    37. Ferrer G, Jung B, Chiu PY, Aslam R, Palacios F, Mazzarello AN, Vergani S, Bagnara D, Chen SS, Yancopoulos S, Xochelli A, Yan XJ, Burger JA, Barrientos JC, Kolitz JE, Allen SL, Stamatopoulos K, Rai KR, Sherry B, Chiorazzi N. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021 11; 35(11):3163-3175. PMID: 33935280; PMCID: PMC8550941.
      Citations: 6     Fields:    Translation:HumansCells
    38. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883. PMID: 33792630; PMCID: PMC8045494.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    39. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038. PMID: 33740268.
      Citations: 1     Fields:    Translation:HumansCells
    40. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021 03 13; 11(3):57. PMID: 33714981; PMCID: PMC7956145.
      Citations: 4     Fields:    Translation:HumansCells
    41. Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Carrasco RD, Wu CJ, Lazarian G, Lefebvre V, Baran-Marszak F, Cymbalista F. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8. PMID: 33689703; PMCID: PMC8034546.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    42. Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina NA, Freyn AW, Snitselaar JL, Gon?alves A, Caniels TG, Burger JA, Poniman M, Chesnais V, Diry S, Iershov A, Ronk AJ, Jangra S, Rathnasinghe R, Brouwer P, Bijl T, van Schooten J, Brinkkemper M, Liu H, Yuan M, Mire CE, van Breemen MJ, Contreras V, Naninck T, Lema?tre J, Kahlaoui N, Relouzat F, Chapon C, Ho Tsong Fang R, McDanal C, Osei-Twum M, St-Amant N, Gagnon L, Montefiori DC, Wilson IA, Ginoux E, de Bree GJ, Garc?a-Sastre A, Schotsaert M, Coughlan L, Bukreyev A, van der Werf S, Guedj J, Sanders RW, van Gils MJ, Le Grand R. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Res Sq. 2021 Feb 15. PMID: 33619476; PMCID: PMC7899470.
      Citations:    
    43. Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 03; 102:106520. PMID: 33611131.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    44. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620. PMID: 33087831.
      Citations: 4     Fields:    Translation:Humans
    45. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301; PMCID: PMC7549397.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    46. Liu W, Burger JA, Xu J, Tang Z, Toruner G, Khanlari M, Medeiros LJ, Tang G. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Ann Hematol. 2020 Oct; 99(10):2343-2349. PMID: 32833105.
      Citations:    Fields:    Translation:Humans
    47. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295. PMID: 32681739.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    48. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432. PMID: 32911375.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    49. Burger JA. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020 07 30; 383(5):460-473. PMID: 32726532.
      Citations: 44     Fields:    Translation:HumansCells
    50. de Castro CG, Burger JA, Gregianin LJ. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma. 2020 10; 61(10):2536-2537. PMID: 32611256.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    51. Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J, Raad II, Burger JA, Garcia-Manero G, Adachi JA. Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020044. PMID: 32670522; PMCID: PMC7340251.
      Citations: 3     
    52. Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020 Dec 15; 60(4):130-137. PMID: 32404571; PMCID: PMC7810251.
      Citations:    Fields:    Translation:HumansCells
    53. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739. PMID: 32170867.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    54. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020 08 01; 26(15):3918-3927. PMID: 32209572; PMCID: PMC8175012.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    55. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513. PMID: 31895947; PMCID: PMC7019190.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    56. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598. PMID: 31862959; PMCID: PMC7272263.
      Citations: 5     Fields:    Translation:HumansCells
    57. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959. PMID: 31537528; PMCID: PMC6887113.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    58. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820. PMID: 31558467; PMCID: PMC7042665.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    59. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019 Nov/Dec; 25(6):386-393. PMID: 31764119; PMCID: PMC7083517.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    60. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085. PMID: 31645416; PMCID: PMC6864283.
      Citations: 9     Fields:    Translation:HumansCells
    61. Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ, Ghia P. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798. PMID: 31628428; PMCID: PMC7214263.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    62. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363. PMID: 31512258; PMCID: PMC6899718.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    63. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487; PMCID: PMC8529949.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    64. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565. PMID: 31502383; PMCID: PMC6825993.
      Citations: 5     Fields:    Translation:Humans
    65. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168. PMID: 31413095; PMCID: PMC7109731.
      Citations: 1     Fields:    Translation:Humans
    66. Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(14):3461-3469. PMID: 31352850.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    67. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4. PMID: 31344256.
      Citations: 2     Fields:    Translation:Humans
    68. Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 09 12; 134(11):851-859. PMID: 31340982; PMCID: PMC6742923.
      Citations: 92     Fields:    Translation:HumansCTClinical Trials
    69. Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger JA, Herzog RW, Engel P, Terhorst C. SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 09; 7(9):1485-1496. PMID: 31315913.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    70. Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(13):3341-3342. PMID: 31305193.
      Citations:    Fields:    Translation:HumansCells
    71. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Valentino R, Chang S, Dean JP, James DF, O'Brien SM, Ghia P. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807. PMID: 31196847; PMCID: PMC6595265.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    72. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409; PMCID: PMC6517659.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    73. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020 01; 11(1):19-23. PMID: 31005650.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    74. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Reddy NM, Kipps TJ, Chang S, Ninomoto J, James DF, Burger JA, Robak T, Tedeschi A, Cymbalista F, Ghia P. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. PMID: 30767298; PMCID: PMC6593416.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    75. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042. PMID: 30842083; PMCID: PMC6509542.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    76. Sivina M, Uriepero A, Berca C, Burger JA, Oppezzo P, Morande PE, Seija N, Fresia P, Landoni AI, Di Noia JM. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood. 2019 05 09; 133(19):2056-2068. PMID: 30814061; PMCID: PMC7022232.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    77. Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A. Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. Br J Haematol. 2019 07; 186(1):175-180. PMID: 30739324.
      Citations: 2     Fields:    Translation:Humans
    78. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS, Ghia P. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188. PMID: 30740654.
      Citations: 4     Fields:    Translation:Humans
    79. Burger JA. Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. Clin Cancer Res. 2019 04 15; 25(8):2372-2374. PMID: 30728153.
      Citations:    Fields:    Translation:Humans
    80. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109. PMID: 30709431.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    81. Boddu P, Gibbons J, Burger J, Sivina M, Thakral B, Kanagal-Shamanna R, Ferrajoli A. Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma. 2019 06; 60(6):1568-1571. PMID: 30632839.
      Citations: 1     Fields:    Translation:Humans
    82. Hamlin PA, Flinn IW, Wagner-Johnston N, Burger JA, Coffey GP, Conley PB, Michelson G, Leeds JM, Der K, Kim Y, Sabalvaro-Torres A, Birrell M, Pandey A, Curnutte JT, Patel MR. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. Am J Hematol. 2019 04; 94(4):E90-E93. PMID: 30592080.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    83. Ten Hacken E, Gounari M, Burger JA, Ghia P. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia. 2019 02; 33(2):287-298. PMID: 30555163; PMCID: PMC7182338.
      Citations: 15     Fields:    Translation:HumansCells
    84. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019. PMID: 30530801; PMCID: PMC6405333.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    85. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574. PMID: 30508305.
      Citations: 26     Fields:    Translation:Humans
    86. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA, Ghia P, Cymbalista F. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569. PMID: 30506764; PMCID: PMC6587776.
      Citations: 24     Fields:    Translation:Humans
    87. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019 05; 185(3):606-608. PMID: 30406944.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    88. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol. 2018 11; 93(11):1318-1326. PMID: 30094870; PMCID: PMC8260004.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    89. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201. PMID: 30307606; PMCID: PMC6800043.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    90. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055. PMID: 30307611; PMCID: PMC6515924.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    91. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na?ve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 11; 93(11):1402-1410. PMID: 30129285; PMCID: PMC6221114.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    92. Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). PMID: 30282833; PMCID: PMC6237462.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    93. Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 04; 60(4):1000-1005. PMID: 30277101.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    94. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961; PMCID: PMC6167965.
      Citations: 10     
    95. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718. PMID: 30263097; PMCID: PMC6154750.
      Citations: 4     Fields:    
    96. Peled A, Klein S, Beider K, Burger JA, Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine. 2018 09; 109:11-16. PMID: 29903571.
      Citations: 32     Fields:    Translation:Humans
    97. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141. PMID: 30028037.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    98. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541; PMCID: PMC6775639.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    99. Burger JA, O'Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018 08; 15(8):510-527. PMID: 29777163.
      Citations: 41     Fields:    Translation:Humans
    100. O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. Safety Analysis of Four Randomized Controlled?Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):648-657.e15. PMID: 30061088.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    101. Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA. Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA). Blood Res. 2018 Jun; 53(2):169-172. PMID: 29963527; PMCID: PMC6021572.
      Citations: 1     
    102. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 09; 103(9):1502-1510. PMID: 29880603; PMCID: PMC6119145.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    103. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747. PMID: 29723397; PMCID: PMC6388399.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    104. Burger JA. New pieces in the BTKi resistance puzzle. Blood. 2018 05 03; 131(18):1995-1996. PMID: 29724714.
      Citations:    Fields:    Translation:Cells
    105. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280. PMID: 29765537; PMCID: PMC5940394.
      Citations: 20     Fields:    
    106. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398. PMID: 29769624; PMCID: PMC6192870.
      Citations: 12     Fields:    Translation:Humans
    107. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691. PMID: 29465264; PMCID: PMC6135679.
      Citations: 10     Fields:    Translation:HumansCells
    108. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. PMID: 29479067.
      Citations: 2     Fields:    Translation:Humans
    109. O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 04 26; 131(17):1910-1919. PMID: 29437592; PMCID: PMC5921964.
      Citations: 155     Fields:    Translation:HumansCTClinical Trials
    110. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832. PMID: 29358183; PMCID: PMC5909764.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    111. Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018 03; 18(3):148-167. PMID: 29348577.
      Citations: 105     Fields:    Translation:HumansCells
    112. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248. PMID: 29352703.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    113. Sivina M, Kim E, Thenhausen T, Krohn-Grimberghe A, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Schliffke S, von Wenserski L, Thiele B, Aky?z N, Falker-Gieske C, Statovci D, Oberle A, Bokemeyer C, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720. PMID: 29632735; PMCID: PMC5889203.
      Citations: 4     Fields:    
    114. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2017; 8:1773. PMID: 29379494; PMCID: PMC5775272.
      Citations: 13     Fields:    
    115. Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A, H?rzschel A. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018 02 05; 215(2):681-697. PMID: 29301866; PMCID: PMC5789417.
      Citations: 27     Fields:    Translation:Humans
    116. Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJ. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185. PMID: 29259203; PMCID: PMC5736707.
      Citations: 67     Fields:    Translation:HumansCellsCTClinical Trials
    117. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 02 22; 131(8):877-887. PMID: 29191916; PMCID: PMC6033052.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    118. Jain P, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z, Nogueras Gonz?lez GM. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40. PMID: 29164608; PMCID: PMC5745295.
      Citations: 11     Fields:    Translation:HumansCells
    119. Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018 01; 27(1):31-42. PMID: 29125406.
      Citations: 22     Fields:    Translation:HumansAnimals
    120. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99. PMID: 29047158.
      Citations: 21     Fields:    Translation:Humans
    121. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430; PMCID: PMC6120342.
      Citations: 4     Fields:    Translation:Humans
    122. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018 04; 32(4):960-970. PMID: 28972595; PMCID: PMC6128536.
      Citations: 55     Fields:    Translation:HumansCells
    123. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901. PMID: 28927784.
      Citations: 45     Fields:    Translation:Humans
    124. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496. PMID: 28798068; PMCID: PMC5709120.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    125. Jain P, Burger JA, Khoury JD. CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol. 2017 10; 92(10):1113-1114. PMID: 28670739; PMCID: PMC5585045.
      Citations: 1     Fields:    Translation:HumansCells
    126. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081. PMID: 28722170; PMCID: PMC5749978.
      Citations: 10     Fields:    Translation:HumansCells
    127. Brown JR, Moslehi J, O'Brien S, Hillmen P, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Cramer P, Jaeger U, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA, Ghia P, Cymbalista F, Dilhuydy MS, Tedeschi A, Dreyling M. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805. PMID: 28751558; PMCID: PMC5622864.
      Citations: 78     Fields:    Translation:Humans
    128. ten Hacken E, Back JW, Shimanovskaya E, Kim E, Burks J, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Burger JA, Gounari M, Scarf? L, Ponzoni M, Ramirez GA, Ghia P. Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 10; 102(10):e394-e396. PMID: 28751563; PMCID: PMC5622869.
      Citations: 5     Fields:    Translation:HumansCells
    129. Havranek O, Xu J, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE, K?hrer S. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017 08 24; 130(8):995-1006. PMID: 28646116; PMCID: PMC5813722.
      Citations: 30     Fields:    Translation:HumansCells
    130. Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 01; 32(1):83-91. PMID: 28592889; PMCID: PMC5770586.
      Citations:    
    131. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. PMID: 28397242; PMCID: PMC6084297.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    132. Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC, Cymbalista F. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615. PMID: 28373262; PMCID: PMC5437732.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    133. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. PMID: 27655665; PMCID: PMC5400650.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    134. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273. PMID: 28171709; PMCID: PMC5980235.
      Citations: 42     Fields:    Translation:Humans
    135. Ten Hacken E, Burger JA. HSP90, a chaperone that can make you SYK. Blood. 2017 02 02; 129(5):542-544. PMID: 28153836.
      Citations: 1     Fields:    Translation:Humans
    136. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618. PMID: 28130399; PMCID: PMC5415425.
      Citations: 12     Fields:    Translation:HumansCells
    137. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017 01 26; 2(2):e89904. PMID: 28138560; PMCID: PMC5256142.
      Citations: 38     Fields:    Translation:Humans
    138. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74. PMID: 28089238; PMCID: PMC5356368.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    139. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747. PMID: 28077600; PMCID: PMC5296363.
      Citations: 53     Fields:    Translation:HumansCells
    140. Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC, O'Brien S, Coutr? SE. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Cancer Res. 2017 Mar 01; 23(5):1149-1155. PMID: 28073846; PMCID: PMC6317338.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    141. Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Davis RE, Burger JA, M?schen M. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017 03 02; 129(9):1155-1165. PMID: 28031181; PMCID: PMC5374732.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    142. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11. PMID: 27673440; PMCID: PMC5361214.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    143. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600. PMID: 27766619; PMCID: PMC7021206.
      Citations: 2     Fields:    Translation:Humans
    144. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158. PMID: 27797975; PMCID: PMC5397369.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    145. Mathur R, Sehgal L, Havranek O, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F, K?hrer S. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017 02; 102(2):373-380. PMID: 27742770; PMCID: PMC5286945.
      Citations: 28     Fields:    Translation:HumansCells
    146. Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016 Oct 04; 7(40):65968-65981. PMID: 27602755; PMCID: PMC5323207.
      Citations: 44     Fields:    Translation:HumansCells
    147. Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2313-2324. PMID: 27697994; PMCID: PMC5417366.
      Citations: 25     Fields:    Translation:HumansCells
    148. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. 2017 Jan; 52(1):28-33. PMID: 27595282; PMCID: PMC5849052.
      Citations: 5     Fields:    Translation:Humans
    149. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479. PMID: 27468087; PMCID: PMC5073031.
      Citations: 9     Fields:    Translation:Humans
    150. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Burger JA, Scielzo C, Ghia P, Caligaris-Cappio F. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016 09 15; 197(6):2522-31. PMID: 27534555; PMCID: PMC5010921.
      Citations: 13     Fields:    Translation:HumansCells
    151. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep; 174(5):760-6. PMID: 27301277; PMCID: PMC5396841.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    152. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. PMID: 27199251; PMCID: PMC4876453.
      Citations: 131     Fields:    Translation:Humans
    153. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 08 15; 122(16):2505-11. PMID: 27182988; PMCID: PMC5980238.
      Citations: 16     Fields:    Translation:Humans
    154. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. PMID: 27151992; PMCID: PMC5004476.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    155. Burger JA. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol. 2016 May; 14(5 Suppl 8):7-12. PMID: 27168204.
      Citations: 1     Fields:    Translation:Humans
    156. Coutre SE, Burger JA, Pagel JM. Discussion: Managing Risk When Using Idelalisib. Clin Adv Hematol Oncol. 2016 May; 14(5 Suppl 8):13. PMID: 27168205.
      Citations: 3     Fields:    Translation:Humans
    157. Burger JA, Styles L, Kipps TJ. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5. PMID: 27096594.
      Citations: 3     Fields:    Translation:Humans
    158. Vitale C, Burger JA. Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opin Pharmacother. 2016 Jun; 17(8):1077-89. PMID: 26988407; PMCID: PMC4955400.
      Citations: 5     Fields:    Translation:Humans
    159. Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Peled A, Davis RE, Konopleva M, Burger JA, M?schen M. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2016 08; 174(3):425-36. PMID: 27071778; PMCID: PMC4959949.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    160. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8. PMID: 27013651; PMCID: PMC5013951.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    161. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008; PMCID: PMC5834229.
      Citations:    Fields:    Translation:Humans
    162. Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Meyer LH, Davis RE, Burger JA, K?hrer S, J?ger U, M?schen M. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 06; 30(6):1246-54. PMID: 26847027; PMCID: PMC5459356.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    163. Burger JA. Obinutuzumab: the more the merrier? Blood. 2016 Jan 07; 127(1):6-8. PMID: 26744434; PMCID: PMC4705611.
      Citations:    Fields:    Translation:Humans
    164. Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res. 2016 05 15; 22(10):2359-67. PMID: 26733610; PMCID: PMC5118034.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    165. Koehrer S, Burger JA. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. 2016 Jan; 14(1):55-65. PMID: 27057669.
      Citations: 12     Fields:    Translation:HumansCells
    166. Okkenhaug K, Burger JA. Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:E1. PMID: 29210027.
      Citations: 1     Fields:    
    167. Okkenhaug K, Burger JA. PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:123-142. PMID: 26350103; PMCID: PMC4704136.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    168. Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2 Investigators, Burger JA, Mayer J. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37. PMID: 26639149; PMCID: PMC4722809.
      Citations: 460     Fields:    Translation:HumansCTClinical Trials
    169. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. ?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73. PMID: 26588193; PMCID: PMC4813299.
      Citations: 10     Fields:    Translation:HumansCells
    170. Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016 Apr; 30(4):833-43. PMID: 26582643; PMCID: PMC4832074.
      Citations:    
    171. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205; PMCID: PMC4826052.
      Citations: 38     Fields:    Translation:Humans
    172. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-na?ve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. PMID: 26472751; PMCID: PMC4732760.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    173. Burger JA, Hartmann EM, Rudelius M, Rosenwald A. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leuk Lymphoma. 2016; 57(3):563-71. PMID: 26458057; PMCID: PMC6699159.
      Citations: 15     Fields:    Translation:HumansCells
    174. Sivina M, Burger JA. The importance of the tissue microenvironment in hairy cell leukemia. Best Pract Res Clin Haematol. 2015 Dec; 28(4):208-16. PMID: 26614899.
      Citations: 3     Fields:    Translation:HumansCells
    175. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140; PMCID: PMC4715651.
      Citations: 28     Fields:    Translation:HumansCells
    176. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885; PMCID: PMC4666803.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    177. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):325-30. PMID: 26290497; PMCID: PMC4794262.
      Citations: 6     Fields:    Translation:Humans
    178. Yilmaz M, Lahoti A, O'Brien S, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE, Nogueras-Gonz?lez GM. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904. PMID: 26217876; PMCID: PMC4519988.
      Citations: 21     Fields:    Translation:Humans
    179. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999; PMCID: PMC4866653.
      Citations: 88     Fields:    Translation:HumansCells
    180. Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016 Mar; 1863(3):401-413. PMID: 26193078; PMCID: PMC4715999.
      Citations: 95     Fields:    Translation:HumansCells
    181. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22. PMID: 25917267; PMCID: PMC4558374.
      Citations: 75     Fields:    Translation:HumansCells
    182. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63. PMID: 25847930; PMCID: PMC4417727.
      Citations: 11     Fields:    Translation:Humans
    183. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7. PMID: 25683856; PMCID: PMC4521389.
      Citations: 2     Fields:    Translation:HumansCells
    184. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Oct; 171(2):281-284. PMID: 25824652; PMCID: PMC4589497.
      Citations: 2     Fields:    
    185. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82. PMID: 25809968; PMCID: PMC5436272.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    186. Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015 May 21; 125(21):3236-45. PMID: 25795921; PMCID: PMC4440880.
      Citations: 63     Fields:    Translation:Humans
    187. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 07; 125(19):2915-22. PMID: 25755291; PMCID: PMC4424415.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    188. Geng H, Hurtz C, Chen Z, Baumjohann D, Chen WY, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Ye BH, Ansel KM, Paietta E, Melnick A, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Lenz KB, Thompson S, Goloviznina NA, Huan J, Bijl JJ, Hunger SP, Kurre P, Chang BH, M?schen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 09; 27(3):409-25. PMID: 25759025; PMCID: PMC4618684.
      Citations: 59     Fields:    Translation:HumansCells
    189. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53. PMID: 25733697; PMCID: PMC4433415.
      Citations: 37     Fields:    Translation:Humans
    190. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14. PMID: 25724525; PMCID: PMC4470787.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    191. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):385-91. PMID: 25817936; PMCID: PMC4905707.
      Citations: 4     Fields:    Translation:Humans
    192. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-na?ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16; 125(16):2497-506. PMID: 25700432; PMCID: PMC4400288.
      Citations: 255     Fields:    Translation:Humans
    193. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7. PMID: 25573991; PMCID: PMC4467871.
      Citations: 121     Fields:    Translation:Humans
    194. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2015 Jul; 170(1):125-8. PMID: 25522014.
      Citations: 7     Fields:    Translation:HumansCells
    195. Badar T, Burger JA, Wierda WG, O'Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol. 2014 Dec; 7(6):705-17. PMID: 25387837; PMCID: PMC4811630.
      Citations: 4     Fields:    Translation:HumansCells
    196. Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46. PMID: 25499217; PMCID: PMC4309260.
      Citations: 20     Fields:    Translation:HumansCells
    197. Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2014 Sep 23; 111(38):13906-11. PMID: 25201956; PMCID: PMC4183279.
      Citations: 39     Fields:    Translation:Humans
    198. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Zacharian G, Huang X, Kantarjian H, Garg N, O'Brien S, Hartmann E, Nogueras-Gonz?lez GM, Rosenwald A. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9. PMID: 25150798; PMCID: PMC4174348.
      Citations: 131     Fields:    Translation:HumansCTClinical Trials
    199. ten Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. 2014 Dec; 144(3):338-48. PMID: 25050922.
      Citations: 21     Fields:    Translation:HumansCells
    200. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501. PMID: 25043749; PMCID: PMC4221361.
      Citations: 3     Fields:    Translation:Humans
    201. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5. PMID: 24859876; PMCID: PMC4116834.
      Citations: 29     Fields:    Translation:HumansCells
    202. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26; 123(26):4132-5. PMID: 24829205; PMCID: PMC4123432.
      Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
    203. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152; PMCID: PMC4055926.
      Citations: 39     Fields:    Translation:HumansCells
    204. Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014 Jun 10; 32(17):1830-9. PMID: 24778403; PMCID: PMC5073382.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    205. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG, Tambaro FP. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. PMID: 24705492; PMCID: PMC4067501.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    206. Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014 Jul; 166(2):177-88. PMID: 24697238; PMCID: PMC4104473.
      Citations: 21     Fields:    Translation:HumansCells
    207. Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kd in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014 Apr; 11(4):184-6. PMID: 24642682; PMCID: PMC4536758.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    208. Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar; 9(1):44-9. PMID: 24357428.
      Citations: 39     Fields:    Translation:Humans
    209. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795; PMCID: PMC3989412.
      Citations: 37     Fields:    Translation:HumansCellsCTClinical Trials
    210. Shanafelt TD, Fegan C, Zucchetto A, Cro L, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V, Bulian P, N?ckel H. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014 Mar 20; 32(9):897-904. PMID: 24516016; PMCID: PMC4876311.
      Citations: 68     Fields:    Translation:Humans
    211. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12):e83830. PMID: 24376763; PMCID: PMC3871531.
      Citations: 43     Fields:    Translation:AnimalsCells
    212. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan; 15(1):48-58. PMID: 24332241; PMCID: PMC4134524.
      Citations: 179     Fields:    Translation:HumansCTClinical Trials
    213. ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res. 2014 Feb 01; 20(3):548-56. PMID: 24323900.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    214. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014 Feb 13; 123(7):1032-9. PMID: 24277076; PMCID: PMC4123413.
      Citations: 81     Fields:    Translation:HumansCells
    215. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5. PMID: 24157581.
      Citations: 19     Fields:    Translation:Humans
    216. Falchi L, Kantarjian HM, Wang X, Verma D, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE, Quint?s-Cardama A. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852; PMCID: PMC3849405.
      Citations: 28     Fields:    Translation:Humans
    217. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014 Feb; 24:71-81. PMID: 24018164.
      Citations: 131     Fields:    Translation:HumansCells
    218. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013 Nov; 54(11):2385-91. PMID: 23425038.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    219. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer. 2013 Nov 01; 119(21):3805-11. PMID: 23943357; PMCID: PMC4535913.
      Citations: 16     Fields:    Translation:Humans
    220. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013 Dec; 34(12):592-601. PMID: 23928062; PMCID: PMC3898793.
      Citations: 128     Fields:    Translation:HumansAnimalsCells
    221. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561; PMCID: PMC3976223.
      Citations: 77     Fields:    Translation:HumansCells
    222. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 04; 369(1):32-42. PMID: 23782158; PMCID: PMC3772525.
      Citations: 845     Fields:    Translation:HumansCTClinical Trials
    223. Burger JA. Osteopontin: an unhealthy sleep remedy for ALL. Blood. 2013 Jun 13; 121(24):4814-5. PMID: 23766457.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    224. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013 Jun 01; 12:50. PMID: 23725032; PMCID: PMC3671957.
      Citations: 37     Fields:    Translation:HumansCells
    225. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62. PMID: 23613521; PMCID: PMC3674666.
      Citations: 158     Fields:    Translation:HumansCellsCTClinical Trials
    226. Burger JA. The CLL cell microenvironment. Adv Exp Med Biol. 2013; 792:25-45. PMID: 24014291.
      Citations: 10     Fields:    Translation:Humans
    227. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013 Feb 10; 31(5):584-91. PMID: 23270003; PMCID: PMC4878047.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    228. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013 Feb 28; 121(9):1501-9. PMID: 23264597; PMCID: PMC4968370.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    229. Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol. 2012 Nov; 24(6):643-9. PMID: 22960555.
      Citations: 34     Fields:    Translation:HumansCells
    230. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616; PMCID: PMC3859239.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    231. Burger JA. BRAF mutation: supporting diversity in HCL. Blood. 2012 Apr 05; 119(14):3193-4. PMID: 22493212.
      Citations: 2     Fields:    
    232. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012 Apr; 13(71):287-97. PMID: 22541616.
      Citations: 59     Fields:    Translation:HumansAnimals
    233. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826; PMCID: PMC4081383.
      Citations: 85     Fields:    Translation:HumansCellsCTClinical Trials
    234. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia. 2012 Aug; 26(8):1812-20. PMID: 22460735.
      Citations: 23     Fields:    Translation:HumansCells
    235. Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012 Mar; 7(1):26-33. PMID: 22105489.
      Citations: 21     Fields:    Translation:HumansCells
    236. Davids MS, Burger JA. Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol. 2012; 3(S1). PMID: 22844583; PMCID: PMC3404599.
      Citations: 25     
    237. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012 Feb 19; 14(3):276-86. PMID: 22344033; PMCID: PMC3290742.
      Citations: 161     Fields:    Translation:HumansAnimalsCells
    238. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul; 26(7):1576-83. PMID: 22362000; PMCID: PMC5459370.
      Citations: 63     Fields:    Translation:HumansCells
    239. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348; PMCID: PMC3907176.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    240. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9. PMID: 22180443; PMCID: PMC4916557.
      Citations: 299     Fields:    Translation:HumansAnimalsCells
    241. Burger JA. The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. Expert Opin Med Diagn. 2012 Jan; 6(1):49-57. PMID: 23480620.
      Citations: 1     Fields:    
    242. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012 Apr; 97(4):599-607. PMID: 22058222; PMCID: PMC3347674.
      Citations: 34     Fields:    Translation:HumansCells
    243. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95. PMID: 21969505; PMCID: PMC4876352.
      Citations: 43     Fields:    Translation:Humans
    244. Burger JA, Hoellenriegel J. Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia.. Oncotarget. 2011 Oct; 2(10):737-8. PMID: 22006556; PMCID: PMC3248155.
      Citations: 12     Fields:    Translation:Humans
    245. Burger JA. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma. 2012 Jan; 53(1):3-4. PMID: 21830996.
      Citations: 1     Fields:    Translation:HumansAnimals
    246. Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011 Nov; 21(5):308-12. PMID: 21945516.
      Citations: 27     Fields:    Translation:HumansCells
    247. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3603-12. PMID: 21803855; PMCID: PMC4916562.
      Citations: 242     Fields:    Translation:HumansCellsCTClinical Trials
    248. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec; 42(12):1989-2000. PMID: 21733558; PMCID: PMC4085742.
      Citations: 11     Fields:    Translation:HumansCells
    249. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98. PMID: 21725050; PMCID: PMC4123422.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    250. Manshouri T, Estrov Z, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40. PMID: 21512135; PMCID: PMC4067142.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    251. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011 Apr; 11(4):621-30. PMID: 21504328.
      Citations: 43     Fields:    Translation:HumansAnimals
    252. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011 Oct 15; 117(20):4689-95. PMID: 21456010.
      Citations: 25     Fields:    Translation:HumansCells
    253. Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:94-8. PMID: 21438839; PMCID: PMC4136471.
      Citations: 7     Fields:    Translation:HumansCells
    254. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:96-103. PMID: 22160019.
      Citations: 82     Fields:    Translation:HumansCells
    255. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. PMID: 21115978; PMCID: PMC3318778.
      Citations: 61     Fields:    Translation:Humans
    256. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol. 2010 Dec; 20(6):424-30. PMID: 20883788.
      Citations: 41     Fields:    Translation:HumansAnimals
    257. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2010 Dec 10; 28(35):e732-4. PMID: 20823404.
      Citations: 4     Fields:    Translation:Humans
    258. Ponader S, Burger JA. Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction? Haematologica. 2010 Sep; 95(9):e5. PMID: 20807980; PMCID: PMC2930977.
      Citations: 1     Fields:    Translation:HumansCells
    259. Burger JA. Angiopoietin-2 in CLL. Blood. 2010 Jul 29; 116(4):508-9. PMID: 20671131.
      Citations:    Fields:    
    260. Quiroga MP, Burger JA. BCR-mediated decrease of CXCR4 and CD62L in CLL. Cancer Res. 2010 Jun 15; 70(12):5194; author reply 5195. PMID: 20501831.
      Citations: 4     Fields:    Translation:Humans
    261. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91. PMID: 20442367; PMCID: PMC2938131.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    262. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8. PMID: 20054352; PMCID: PMC10405622.
      Citations:    Fields:    Translation:HumansCells
    263. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009 Dec 15; 15(24):7456-7461. PMID: 19996200; PMCID: PMC2795094.
      Citations: 12     Fields:    
    264. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93. PMID: 19895616; PMCID: PMC4476391.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    265. Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009 Sep 17; 114(12):2560-1; author reply 2561-2. PMID: 19762501; PMCID: PMC4969051.
      Citations: 9     Fields:    Translation:Humans
    266. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Gandhi V, Kay NE, Plunkett W, Burger JA, J?ger U. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. PMID: 19762485; PMCID: PMC4081374.
      Citations: 151     Fields:    Translation:HumansAnimalsCells
    267. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009 Oct 15; 114(16):3367-75. PMID: 19636060; PMCID: PMC4969052.
      Citations: 202     Fields:    Translation:HumansAnimalsCells
    268. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43. PMID: 19567878; PMCID: PMC4186638.
      Citations: 37     Fields:    Translation:HumansCells
    269. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37. PMID: 19491390; PMCID: PMC4916941.
      Citations: 103     Fields:    Translation:HumansAnimalsCells
    270. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs. 2009 Apr; 18(4):481-90. PMID: 19335276.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    271. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009 May 28; 113(22):5549-57. PMID: 19318683; PMCID: PMC4580965.
      Citations: 59     Fields:    Translation:HumansCells
    272. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009 May 07; 113(19):4604-13. PMID: 19228923; PMCID: PMC4969050.
      Citations: 76     Fields:    Translation:HumansCells
    273. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43. PMID: 19224852; PMCID: PMC4890649.
      Citations: 28     Fields:    Translation:Humans
    274. Burger JA. CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you. Leuk Res. 2009 Jun; 33(6):747-8. PMID: 19091405.
      Citations: 3     Fields:    Translation:Humans
    275. Burger JA, Quiroga MP, Hartmann E, Wierda WG, Keating MJ, Rosenwald A, B?rkle A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009 Mar 26; 113(13):3050-8. PMID: 19074730; PMCID: PMC4916945.
      Citations: 145     Fields:    Translation:HumansCells
    276. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009 Jan; 23(1):43-52. PMID: 18987663.
      Citations: 181     Fields:    Translation:HumansAnimals
    277. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53. PMID: 18836097; PMCID: PMC2614629.
      Citations: 68     Fields:    Translation:HumansCells
    278. Niedermeier M, Wierda WG, Keating MJ, Burger JA, B?rkle A, Schmitt-Gr?ff A. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3316-25. PMID: 17652619.
      Citations: 88     Fields:    Translation:HumansCells
    279. Burger JA, B?rkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007 May; 137(4):288-96. PMID: 17456052.
      Citations: 54     Fields:    Translation:Humans
    280. Burger JA. No cell is an island unto itself: the stromal microenvironment in chronic lymphocytic leukemia. Leuk Res. 2007 Jul; 31(7):887-8. PMID: 17234265.
      Citations: 4     Fields:    Translation:HumansCells
    281. Burger JA, Seiler L, Schmitt-Gr?ff A, B?rkle A, Finke J. Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. Leuk Lymphoma. 2006 Nov; 47(11):2427-30. PMID: 17107924.
      Citations: 1     Fields:    Translation:Humans
    282. Spoo AC, Wierda WG, Burger JA, L?bbert M. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007 Jan 15; 109(2):786-91. PMID: 16888090.
      Citations: 125     Fields:    Translation:Humans
    283. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7. PMID: 16269611.
      Citations: 437     Fields:    Translation:HumansAnimalsCells
    284. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 2005 Jun 23; 24(27):4462-71. PMID: 15806155.
      Citations: 103     Fields:    Translation:HumansCells
    285. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30. PMID: 15905192.
      Citations: 102     Fields:    Translation:HumansCells
    286. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene. 2005 Mar 17; 24(12):2067-75. PMID: 15688008.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    287. Zeiser R, Mikesch K, Fisch P, Schaefer HE, Burger JA. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol. 2004 Jun; 125(6):679. PMID: 15180856.
      Citations:    Fields:    Translation:HumansCells
    288. Hartmann TN, Burger M, Burger JA. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. J Biol Regul Homeost Agents. 2004 Apr-Jun; 18(2):126-30. PMID: 15471215.
      Citations: 14     Fields:    Translation:HumansCells
    289. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Behringer DM, Schulte-M?nting J. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br J Haematol. 2004 Mar; 124(6):762-8. PMID: 15009064.
      Citations: 13     Fields:    Translation:Humans
    290. Burger M, Glodek A, Hartmann T, Silberstein LE, Fujii N, Kipps TJ, Burger JA, Schmitt-Gr?ff A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101. PMID: 14603250.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    291. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol. 2003 Aug; 122(4):579-89. PMID: 12899713.
      Citations: 30     Fields:    Translation:HumansCells
    292. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6. PMID: 12002747.
      Citations: 57     Fields:    Translation:HumansCells
    293. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7. PMID: 11807009.
      Citations: 101     Fields:    Translation:HumansCells
    294. Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol. 2001 Sep; 108(3):417-23. PMID: 11544462.
      Citations: 9     Fields:    Translation:HumansCells
    295. Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine. 2001 Feb 28; 19(15-16):2181-9. PMID: 11228391.
      Citations: 7     Fields:    Translation:AnimalsCells
    296. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest. 2001 Feb; 107(3):305-15. PMID: 11160154; PMCID: PMC199194.
      Citations: 56     Fields:    Translation:HumansCells
    297. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000 Oct 15; 96(8):2655-63. PMID: 11023495.
      Citations: 295     Fields:    Translation:HumansCells
    298. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, Maini RN. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000; 2(6):477-88. PMID: 11056678; PMCID: PMC17820.
      Citations: 188     Fields:    Translation:HumansCells
    299. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000 Mar; 108(3):641-52. PMID: 10759724.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    300. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999 Dec 01; 94(11):3658-67. PMID: 10572077.
      Citations: 181     Fields:    Translation:HumansCells
    301. Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol. 1999 Aug 15; 163(4):2017-22. PMID: 10438939.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    302. Burger JA, Engelhardt A, Ketelsen UP, Schollmeyer P, Sach M. [Temporary hemiparesis and Raynaud symptoms in eosinophilic fasciitis]. Internist (Berl). 1997 Jul; 38(7):688-91. PMID: 9333603.
      Citations:    Fields:    Translation:Humans
    303. Sach M, Bauermeister K, Burger JA, Loetscher P, Elsner J, Schollmeyer P, Dobos GJ. Inverse MCP-1/IL-8 ratio in effluents of CAPD patients with peritonitis and in isolated cultured human peritoneal macrophages. Nephrol Dial Transplant. 1997 Feb; 12(2):315-20. PMID: 9132652.
      Citations: 3     Fields:    Translation:HumansCells
    304. Burger JA, Ochs A, Wirth K, Berger DP, Mertelsmann R, Engelhardt R, Roessle M, Haag K. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol. 1997 Feb; 8(2):200-2. PMID: 9093733.
      Citations: 6     Fields:    Translation:Humans
    305. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia. 1997 Feb; 11(2):281-3. PMID: 9009093.
      Citations: 4     Fields:    Translation:HumansCells
    306. Burger JA, Schöffel U, Sach M, Jacobs E, Kownatzki E, von Specht BU, Farthmann EH. Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Eur J Surg. 1995 Sep; 161(9):647-53. PMID: 8541423.
      Citations: 1     Fields:    Translation:HumansCells
    307. Sach M, Loetscher P, Burger JA, Knopf HP, Schollmeyer P, Dobos GJ. MCP-1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages. Adv Perit Dial. 1995; 11:19-23. PMID: 8534702.
      Citations: 1     Fields:    Translation:HumansCells
    308. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia.
    309. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    310. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7.
    311. Targeting CXCR4 in chronic lymphocytic leukemia. 369-385.
    312. PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Current Topics in Microbiology and Immunology. 393:123-142.
    313. Cell trafficking in chronic lymphocytic leukemia. Open Hematology Journal. 3.
    314. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clinical Advances in Hematology and Oncology. 14:55-65.
    315. Fledgling prognostic markers in CLL. Blood. 110:3820-3821.
    316. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.
    317. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 30:325-330.
    318. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    319. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia. Biochimica et Biophysica Acta - Molecular Cell Research.
    320. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. British Journal of Haematology.
    321. The microenvironment in chronic lymphocytic leukemia. 56-71.
    322. Ibrutinib Is effective in relapsed CLL. Cancer Discovery. 3.
    323. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    324. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.
    325. The CLL cell microenvironment. 25-45.
    326. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    327. Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research. 22:2359-2367.
    328. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer.
    329. The importance of the tissue microenvironment in hairy cell leukemia. Best Practice and Research: Clinical Haematology. 28:208-216.
    330. Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia. Journal of Immunology. 197:2522-2531.
    331. Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell. 27:409-425.
    332. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    333. Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.
    334. Chronic lymphocytic leukemia therapy. Expert Opinion on Pharmacotherapy. 1-13.
    335. β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 122:565-573.
    336. Hematological neoplasia. 400-526.
    337. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. The Lancet Oncology. 15:48-58.
    338. Haematologica. 101:e295-e298.
    339. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 126:2686-2694.
    340. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 101:e254-e258.
    341. Nurse-like cells that support leukemic B cell survival are highly effective antigen presenting cells. Blood. 96.
    342. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia.
    343. Bendamustine in B-cell malignancies. Clinical Cancer Research. 15:7456-7461.
    344. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. British Journal of Haematology.
    345. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    346. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia.
    347. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.
    348. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma.
    349. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    350. Obinutuzumab. Blood. 127:6-8.
    351. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. British Journal of Haematology. 171:281-284.
    352. Special diagnostics. 39-64.
    353. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplantation. 52:28-33.
    354. Nurse-like cells that support survival of chronic lymphocytic leukemia cells are derived from blood monocytes. Blood. 96.
    355. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.
    356. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 7:65968-65981.
    357. The bone marrow microenvironment and its impact in acute and chronic B cell malignancies. 35-45.
    BURGER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (720)
    Explore
    _
    Co-Authors (104)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _